Skip to main content
Top
Published in: Obesity Surgery 12/2019

01-12-2019 | Obesity | Review

Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery

Authors: Alexis C Sudlow, Carel W le Roux, Dimitri J Pournaras

Published in: Obesity Surgery | Issue 12/2019

Login to get access

Abstract

There is a growing need for treatments for patients who would benefit from further weight loss following bariatric surgery or weight loss maintenance/long-term disease remission. Currently, therapeutic options are limited. Although largely dismissed previously, advances in weight loss pharmacotherapy now offer the possibility of achieving clinically significant weight loss. Historical comparisons drawn between the effects of medications vs surgery are generally inaccurate as novel classes of anti-obesity pharmacotherapy have since been developed and moreover, reflect an outdated approach in comparing medicine with surgery. Herein, we provide an overview of the most recently developed anti-obesity medications which may not only present a potentially innovative approach to medical treatment of obesity but may also inspire renewed enthusiasm for investigating what can be achieved through multimodal care.
Literature
1.
go back to reference Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish Obese subjects. N Engl J Med. 2007;357(8):741–52.PubMedCrossRef Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish Obese subjects. N Engl J Med. 2007;357(8):741–52.PubMedCrossRef
3.
go back to reference Franz MJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. J Acad Nutr Diet. 2015;115(9):1447–63.PubMedCrossRef Franz MJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. J Acad Nutr Diet. 2015;115(9):1447–63.PubMedCrossRef
4.
go back to reference Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84(10):3434–8.PubMedPubMedCentralCrossRef Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84(10):3434–8.PubMedPubMedCentralCrossRef
5.
go back to reference Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(2):1239–46.PubMedCrossRef Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(2):1239–46.PubMedCrossRef
6.
go back to reference Navarro M, De Fonseca R, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neruochem. 1996;67(5):1982–91.CrossRef Navarro M, De Fonseca R, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neruochem. 1996;67(5):1982–91.CrossRef
7.
go back to reference Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and two year outcomes. Ann Surg. 2010;252(6):966–71.PubMedCrossRef Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and two year outcomes. Ann Surg. 2010;252(6):966–71.PubMedCrossRef
8.
go back to reference Pournaras DJ, Aasheim ET, Bueter M, et al. Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis. 2012;8(4):371–4.PubMedCrossRef Pournaras DJ, Aasheim ET, Bueter M, et al. Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis. 2012;8(4):371–4.PubMedCrossRef
9.
go back to reference Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomised, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med. 2015;373(7):11–22.PubMedCrossRef Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomised, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med. 2015;373(7):11–22.PubMedCrossRef
10.
go back to reference Fujikoa K, O’Neil P, Davies M, et al. Early weight loss with liraglutide 3.0mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016;24(11):2278–88.CrossRef Fujikoa K, O’Neil P, Davies M, et al. Early weight loss with liraglutide 3.0mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016;24(11):2278–88.CrossRef
11.
12.
go back to reference Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.PubMedCrossRef Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.PubMedCrossRef
13.
go back to reference Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef
14.
go back to reference O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose ranging, phase 2 trial. Lancet. 2018;392(10148):637–49.PubMedCrossRef O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose ranging, phase 2 trial. Lancet. 2018;392(10148):637–49.PubMedCrossRef
15.
go back to reference Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity. 2012;11(4):556–62.CrossRef Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity. 2012;11(4):556–62.CrossRef
16.
go back to reference Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedCrossRef Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.PubMedCrossRef
17.
go back to reference Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomised, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRef Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomised, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCrossRef
18.
go back to reference Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. PT. 2013;38(9):525–34. Gustafson A, King C, Rey JA. Lorcaserin (Belviq): a selective serotonin 5-HT2C agonist in the treatment of obesity. PT. 2013;38(9):525–34.
19.
go back to reference Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.PubMedCrossRef Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.PubMedCrossRef
20.
go back to reference Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.PubMedCrossRef Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.PubMedCrossRef
21.
go back to reference Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107–17.PubMedCrossRef Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107–17.PubMedCrossRef
22.
go back to reference Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836–41.PubMedCrossRef Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836–41.PubMedCrossRef
23.
go back to reference Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2008;17(1):30–9.PubMedCrossRef Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2008;17(1):30–9.PubMedCrossRef
24.
go back to reference Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–43.PubMedCrossRef Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–43.PubMedCrossRef
25.
go back to reference Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomised clinical trial. JAMA. 2016;315(10):990–1004.PubMedCrossRef Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomised clinical trial. JAMA. 2016;315(10):990–1004.PubMedCrossRef
26.
go back to reference Bays HE, Weinstein R, Law G, et al. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity. 2014;22(4):1042–9.PubMedCrossRef Bays HE, Weinstein R, Law G, et al. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity. 2014;22(4):1042–9.PubMedCrossRef
27.
go back to reference Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.PubMedCrossRef Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.PubMedCrossRef
28.
go back to reference Malin SK, Kashyap SR. Effects of metformin on weight loss. Curr Opin Endocrinol Diabetes Obes. 2014;21(10):323–9.PubMedCrossRef Malin SK, Kashyap SR. Effects of metformin on weight loss. Curr Opin Endocrinol Diabetes Obes. 2014;21(10):323–9.PubMedCrossRef
29.
go back to reference Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004;18(4):CD003418. Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004;18(4):CD003418.
30.
go back to reference Diabetes Prevention Programme Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Programme Outcomes Study. Lancet. 2009;374(9702):1677–86.CrossRef Diabetes Prevention Programme Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Programme Outcomes Study. Lancet. 2009;374(9702):1677–86.CrossRef
31.
go back to reference Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641. Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641.
32.
go back to reference Hutcheon DA, Hale AL, Ewing JA, et al. Short-term preoperative weight loss and postoperative outcomes in bariatric surgery. J Am Coll Surg. 2018;226(4):514–24.PubMedCrossRef Hutcheon DA, Hale AL, Ewing JA, et al. Short-term preoperative weight loss and postoperative outcomes in bariatric surgery. J Am Coll Surg. 2018;226(4):514–24.PubMedCrossRef
33.
go back to reference Malone M, Alger-Mayer SA, Lindstrom J. Use of orlistat 60 mg in the management of weight loss before bariatric surgery. Ann Pharmacother. 2012;46(6):779–84.PubMedCrossRef Malone M, Alger-Mayer SA, Lindstrom J. Use of orlistat 60 mg in the management of weight loss before bariatric surgery. Ann Pharmacother. 2012;46(6):779–84.PubMedCrossRef
34.
go back to reference Guisado-Macias JA, Mendez-Sanchez F, Baltasar-Tello I, et al. Fluoxetine, topiramate, and combination of both to stabilize eating behaviour before bariatric surgery. Actas Esp Psiquiatr. 2016;44(3):93–6.PubMed Guisado-Macias JA, Mendez-Sanchez F, Baltasar-Tello I, et al. Fluoxetine, topiramate, and combination of both to stabilize eating behaviour before bariatric surgery. Actas Esp Psiquiatr. 2016;44(3):93–6.PubMed
35.
go back to reference Aberle J, Freier A, Busch P, et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes Surg. 2009;19(11):1504–7.PubMedCrossRef Aberle J, Freier A, Busch P, et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes Surg. 2009;19(11):1504–7.PubMedCrossRef
37.
go back to reference King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320(15):1560–9.PubMedPubMedCentralCrossRef King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320(15):1560–9.PubMedPubMedCentralCrossRef
38.
go back to reference Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72.PubMedCrossRef Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72.PubMedCrossRef
39.
go back to reference Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-centre study. Surg Obes Relat Dis. 2017;13(3):491–500.PubMedCrossRef Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-centre study. Surg Obes Relat Dis. 2017;13(3):491–500.PubMedCrossRef
40.
go back to reference Nor-Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8.PubMedCrossRef Nor-Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8.PubMedCrossRef
41.
go back to reference Suliman M, Buckley A, Al-Tikriti A, et al. Routine clinical use of liraglutide 3mg for the treatment of obesity: outcomes in non-surgical and bariatric surgical patients. Diabetes Obes Metab. 2019;21(6):1498–501.PubMedCrossRef Suliman M, Buckley A, Al-Tikriti A, et al. Routine clinical use of liraglutide 3mg for the treatment of obesity: outcomes in non-surgical and bariatric surgical patients. Diabetes Obes Metab. 2019;21(6):1498–501.PubMedCrossRef
42.
go back to reference Gorgojo-Martinez J, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–65.PubMedCrossRef Gorgojo-Martinez J, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–65.PubMedCrossRef
43.
go back to reference Shehadeh N, Zaid WA, Zuckerman Levin N, et al. Liraglutide treatment in post-bariatric surgery patients who failed to maintain weight reduction. Surg Obes Relat Dis. 2017;13(10):S144.CrossRef Shehadeh N, Zaid WA, Zuckerman Levin N, et al. Liraglutide treatment in post-bariatric surgery patients who failed to maintain weight reduction. Surg Obes Relat Dis. 2017;13(10):S144.CrossRef
44.
go back to reference Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(5):191–5.PubMedCrossRef Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(5):191–5.PubMedCrossRef
45.
go back to reference Rye P, Modi R, Cawsey S, et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.PubMedCrossRef Rye P, Modi R, Cawsey S, et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.PubMedCrossRef
46.
go back to reference Shwartz J, Chaudhry UI, Suzo A, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.CrossRef Shwartz J, Chaudhry UI, Suzo A, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.CrossRef
47.
go back to reference Jester L, Wittgrove AC, Clark W. Adjunctive use of appetite suppressant medications for improved weight management in bariatric surgical patients. Obes Surg. 1996;6(5):412–5.PubMedCrossRef Jester L, Wittgrove AC, Clark W. Adjunctive use of appetite suppressant medications for improved weight management in bariatric surgical patients. Obes Surg. 1996;6(5):412–5.PubMedCrossRef
48.
go back to reference Zilberstein B, Pajecki D. Garcia de Brito A, Gallafrio ST, Eshkenazy R, Andrade CG. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg. 2004;14(6):802–5.PubMedCrossRef Zilberstein B, Pajecki D. Garcia de Brito A, Gallafrio ST, Eshkenazy R, Andrade CG. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg. 2004;14(6):802–5.PubMedCrossRef
49.
go back to reference Toth AT, Gomez G, Shukla A, et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-centre study. Children. 2018;5(9)PubMedCentralCrossRef Toth AT, Gomez G, Shukla A, et al. Weight loss medications in young adults after bariatric surgery for weight regain or inadequate weight loss: a multi-centre study. Children. 2018;5(9)PubMedCentralCrossRef
50.
go back to reference Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7.PubMedCrossRef Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7.PubMedCrossRef
51.
go back to reference Stanford FC, Toth AT, Shukla AP, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicentre study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8.PubMedPubMedCentralCrossRef Stanford FC, Toth AT, Shukla AP, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicentre study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8.PubMedPubMedCentralCrossRef
52.
go back to reference Creange C, Lin E, Ren-Fielding C, et al. Use of liraglutide for weight loss in patients with prior bariatric surgery. Surg Obes Relat Dis. 2016;12(7):S157. Creange C, Lin E, Ren-Fielding C, et al. Use of liraglutide for weight loss in patients with prior bariatric surgery. Surg Obes Relat Dis. 2016;12(7):S157.
53.
go back to reference Gutt S, Schraier S, Gonzalez Bagnes MF, et al. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):393–947.CrossRef Gutt S, Schraier S, Gonzalez Bagnes MF, et al. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):393–947.CrossRef
54.
go back to reference Hanjieva-Darlenska T, Handjiev S, Larsen TM, et al. Initial weight loss on an 800-kcal diet as a predictor of weight loss success after 8 weeks: the Diogenes study. Eur J Clin Nutr. 2010;64(9):994–9.CrossRef Hanjieva-Darlenska T, Handjiev S, Larsen TM, et al. Initial weight loss on an 800-kcal diet as a predictor of weight loss success after 8 weeks: the Diogenes study. Eur J Clin Nutr. 2010;64(9):994–9.CrossRef
55.
go back to reference Rissanen A, Lean M, Rössner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord. 2003;27(1):103–9.PubMedCrossRef Rissanen A, Lean M, Rössner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord. 2003;27(1):103–9.PubMedCrossRef
56.
go back to reference Fujioka K, Plodkowski R, O’Neil PM, et al. The relationship between early and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes. 2016;40(9):1369–75.CrossRef Fujioka K, Plodkowski R, O’Neil PM, et al. The relationship between early and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes. 2016;40(9):1369–75.CrossRef
57.
58.
go back to reference Welbourn R, le Roux C, Owen-Smith A, et al. Why the NHS should do more bariatric surgery; how much should we do? BMJ. 2016;353:i1472.PubMedCrossRef Welbourn R, le Roux C, Owen-Smith A, et al. Why the NHS should do more bariatric surgery; how much should we do? BMJ. 2016;353:i1472.PubMedCrossRef
60.
go back to reference Xia Y, Kelton CM, Guo JJ, et al. Treatment of obesity: pharmacotherapy trends in the United States from 1999-2010. Obesity. 2015;23(8):1721–8.PubMedCrossRef Xia Y, Kelton CM, Guo JJ, et al. Treatment of obesity: pharmacotherapy trends in the United States from 1999-2010. Obesity. 2015;23(8):1721–8.PubMedCrossRef
61.
go back to reference Thomas CE, Mauer EA, Shukla AP, et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity. 2016;24(9):1955–61.PubMedCrossRef Thomas CE, Mauer EA, Shukla AP, et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity. 2016;24(9):1955–61.PubMedCrossRef
62.
go back to reference Pournaras DJ, le Roux CW. Type 2 diabetes: multimodal treatment of a complex disease. Lancet. 2015;386(9):936–37.CrossRef Pournaras DJ, le Roux CW. Type 2 diabetes: multimodal treatment of a complex disease. Lancet. 2015;386(9):936–37.CrossRef
63.
go back to reference Gesquiere I, Steenackers N, Lannoo M, et al. Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study. J Trace Elem Med Biol. 2019;52(3):68–73.PubMedCrossRef Gesquiere I, Steenackers N, Lannoo M, et al. Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study. J Trace Elem Med Biol. 2019;52(3):68–73.PubMedCrossRef
64.
go back to reference Arzan C, Porat D, Fine-Shamir N, et al. Oral levothyroxine therapy post bariatric surgery: biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019;15(2):333–41.CrossRef Arzan C, Porat D, Fine-Shamir N, et al. Oral levothyroxine therapy post bariatric surgery: biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019;15(2):333–41.CrossRef
Metadata
Title
Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery
Authors
Alexis C Sudlow
Carel W le Roux
Dimitri J Pournaras
Publication date
01-12-2019
Publisher
Springer US
Published in
Obesity Surgery / Issue 12/2019
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-04206-7

Other articles of this Issue 12/2019

Obesity Surgery 12/2019 Go to the issue